Rothschild Asset Management Inc. purchased a new position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 1,312,334 shares of the biopharmaceutical company’s stock, valued at approximately $23,491,000. Rothschild Asset Management Inc. owned about 2.93% of Vanda Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc. grew its position in Vanda Pharmaceuticals by 7.5% in the 2nd quarter. Vanguard Group Inc. now owns 2,680,895 shares of the biopharmaceutical company’s stock worth $43,698,000 after purchasing an additional 186,548 shares during the last quarter. Macquarie Group Ltd. grew its position in Vanda Pharmaceuticals by 10.9% in the 3rd quarter. Macquarie Group Ltd. now owns 1,890,085 shares of the biopharmaceutical company’s stock worth $33,833,000 after purchasing an additional 186,526 shares during the last quarter. State Street Corp grew its position in Vanda Pharmaceuticals by 2.9% in the 2nd quarter. State Street Corp now owns 1,618,485 shares of the biopharmaceutical company’s stock worth $26,380,000 after purchasing an additional 46,299 shares during the last quarter. Renaissance Technologies LLC grew its position in Vanda Pharmaceuticals by 16.9% in the 2nd quarter. Renaissance Technologies LLC now owns 1,097,950 shares of the biopharmaceutical company’s stock worth $17,897,000 after purchasing an additional 158,700 shares during the last quarter. Finally, Stonepine Capital Management LLC grew its position in Vanda Pharmaceuticals by 1,482.2% in the 2nd quarter. Stonepine Capital Management LLC now owns 685,086 shares of the biopharmaceutical company’s stock worth $11,167,000 after purchasing an additional 641,786 shares during the last quarter. Institutional investors own 92.84% of the company’s stock.

Several research firms have issued reports on VNDA. Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $25.00 price target on shares of Vanda Pharmaceuticals in a research report on Sunday, November 12th. ValuEngine lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. Zacks Investment Research lowered shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, October 26th. Finally, Piper Jaffray Companies set a $26.00 target price on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, October 19th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. Vanda Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $21.50.

TRADEMARK VIOLATION WARNING: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/11/23/rothschild-asset-management-inc-invests-23-49-million-in-vanda-pharmaceuticals-inc-vnda-stock.html.

Shares of Vanda Pharmaceuticals Inc. (VNDA) traded down $0.15 during trading on Thursday, hitting $13.00. 229,100 shares of the stock traded hands, compared to its average volume of 554,235. Vanda Pharmaceuticals Inc. has a 1-year low of $11.90 and a 1-year high of $18.99.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). Vanda Pharmaceuticals had a negative net margin of 9.01% and a negative return on equity of 10.99%. The firm had revenue of $41.30 million during the quarter, compared to the consensus estimate of $43.90 million. During the same period last year, the firm posted ($0.01) EPS. The firm’s quarterly revenue was up 7.3% on a year-over-year basis. analysts anticipate that Vanda Pharmaceuticals Inc. will post -0.42 earnings per share for the current year.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Stock Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.